Buckley Capital Sees 50%+ Upside for Liquidia on Yutrepia Ruling and Buyout Potential

Analyst
โดย Insider Monkey·Read original
Summary · why it matters

Buckley Capital Advisors believes Liquidia Corporation still has more than 50% upside based on what an acquirer would pay, driven by an expected favorable court ruling on its Yutrepia product for pulmonary hypertension associated with interstitial lung disease. The firm disclosed in its second-quarter 2026 investor letter that it originally purchased Liquidia at $5.00 per share, with an average cost around $9.00, and the stock traded at about $78 at the time of writing. Buckley Capital noted that Liquidia has been its largest year-to-date contributor, up over 100%, and that it continues to manage its position using options. The firm is awaiting Judge Andrews' decision, which it expects will be in Liquidia's favor, and anticipates a potential acquirer emerging shortly after the ruling.

Impact on stocks 1

Biotech & Genomic Medicine▲ · 1 stocks

Off-coverage companies 1

Buckley Capital AdvisorsPrivate± Mixed
relevance

© 2026 MarketDXNews